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Background: A suggested benefit of sublobar resection for stage I non-small cell lung cancer (NSCLC) compared to
lobectomy is a relative preservation of pulmonary function. Very little objective data exist, however, supporting this
supposition. We sought to evaluate the relative impact of both anatomic segmental and lobar resection on
pulmonary function in patients with resected clinical stage I NSCLC.
Methods: The records of 159 disease-free patients who underwent anatomic segmentectomy (n = 89) and lobectomy
(n = 70) for the treatment of stage I NSCLC with pre- and postoperative pulmonary function tests performed between 6
to 36 months after resection were retrospectively reviewed. Changes in forced expiratory volume in one second (FEV1)
and diffusion capacity of carbon monoxide (DLCO) were analyzed based upon the number of anatomic pulmonary
segments removed: 1–2 segments (n = 77) or 3–5 segments (n = 82).
Results: Preoperative pulmonary function was worse in the lesser resection cohort (1–2 segments) compared to the
greater resection group (3–5 segments) (FEV1(%predicted): 79% vs. 85%, p = 0.038; DLCO(%predicted): 63% vs. 73%, p = 0.010).
A greater decline in FEV1 was noted in patients undergoing resection of 3–5 segments (FEV1 (observed): 0.1 L vs. 0.3 L,
p = 0.003; and FEV1 (% predicted): 4.3% vs. 8.2%, p = 0.055). Changes in DLCO followed this same trend (DLCO(observed): 1.3
vs. 2.4 mL/min/mmHg, p = 0.015; and DLCO(% predicted): 3.6% vs. 5.9%, p = 0.280).
Conclusions: Parenchymal-sparing resections resulted in better preservation of pulmonary function at a median of one
year, suggesting a long-term functional benefit with small anatomic segmental resections (1–2 segments). Prospective
studies to evaluate measurable functional changes, as well as quality of life, between segmentectomy and lobectomy
with a larger patient cohort appear justified.
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Arguments over the extent of parenchymal resection
for the small peripheral lung cancer have been waged
since the earliest attempts at surgical management of
this disease [1-9]. The primary concern of oncologic
adequacy of resection between sublobar resection and
lobectomy or pneumonectomy has always been the
primary point of contention. However, preservation of* Correspondence: macke@surgery.wisc.edu
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unless otherwise stated.vital pulmonary function has also been a major
consideration in choosing less than lobectomy for the
small peripheral lung cancer. There are conflicting
reports in the surgical literature related to the utility
of sublobar resection, particularly anatomic segmen-
tectomy, in preserving precious lung function
compared to lobectomy for early stage lung cancer
[8,10-13]. These conflicting reported outcomes led us
to retrospectively review our experience with anatomic
segmentectomy and lobectomy for disease-free, stage I
peripheral NSCLC patients to assess the long-term
impact of resection on pulmonary function.This is an Open Access article distributed under the terms of the Creative
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This study was approved by the Institutional Review
Board of the University of Pittsburgh. The need for indi-
vidual consent was waived given the retrospective nature
of the analysis. Disease-free patients with a history of clin-
ical stage I NSCLC who underwent surgical resection by
anatomic segmentectomy (n = 89) or lobectomy (n = 70)
from 2002 to 2010 with full preoperative and postopera-
tive pulmonary function testing (PFT) were identified
from the Thoracic Tumor Registry and billing records
of the Department of Cardiothoracic Surgery at the
University of Pittsburgh Medical Center. Only patients
with PFT’s performed between 6 months to 36 months
postoperatively were included in this study. Data col-
lected from electronic or paper medical records in-
cluded patient demographics, PFT results, operative
details, and tumor characteristics (Table 1).
As was the methodology of an earlier report assessing
pulmonary functional loss differences between segmen-
tectomy and lobectomy done by Harada et al. [11], each
lobe of the lungs was segregated into their classical ana-
tomic segments. The lower lobes were deemed to have 5
pulmonary segments, the right upper lobe to have 3 seg-
ments, the right middle lobe to have 2 segments, and left
upper lobe to have 4 segments. Given that the basilar
segmental group has 4 segments, the volume of lung
parenchyma resected during basilar segmentectomy is
more similar to that of an upper or lower lobectomy.
Also, given that right middle lobes have only 2 segments,
the volume resected for middle lobes is more consistent
with a 1 or 2 segment segmentectomy. Therefore we
chose to define the cohorts as those who had 1–2 seg-
ments resected (n = 77) and those who had 3–5 segmentsTable 1 Preoperative demographics, tumor
characteristics, and operative details
1-2 Segments 3-5 Segments P value
(n = 77) (n = 82)
Male sex 33 (42.9%) 42 (51.2%) 0.341
Age 69 ± 9 69 ± 10 0.818
Tumor size 1.9 ± 0.9 2.9 ± 1.9 <0.001
Tumor location
Right upper lobe 27 (35.1%) 28 (34.1%) 1
Right middle lobe 9 (11.7%)
Right lower lobe 9 (11.7%) 20 (24.4%) 0.042
Left upper lobe 27 (35.1%) 12 (14.6%) 0.003
Left lower lobe 5 (6.5%) 22 (26.8%) <0.001
Approach 0.257
Thoracotomy 27 (35.1%) 37 (45.1%)
VATS 50 (64.9%) 45 (54.9%)
Mean # of segments resected 1.4 ± 0.5 4.0 ± 0.8 <0.001resected (n = 82). Basilar segmental resections were
grouped in the greater resection cohort and middle lobec-
tomies in the lesser resection cohort.
All patients underwent thorough preoperative staging
with computed tomography scanning, with or without
positron emission tomography, typically within 6 weeks
of surgical resection. Additional diagnostic testing (brain
magnetic resonance imaging, bone scan) was performed
as warranted by patient symptoms and other clinical
findings or at the discretion of the individual surgeon.
Invasive mediastinal staging, such as endobronchial
ultrasound with fine-needle aspiration or mediastinos-
copy, was not routinely performed in the preoperative
evaluation of these patients, unless mediastinal nodes
were greater than 1 centimeter in diameter. All patients
were clinically staged preoperatively as IA or IB accord-
ing to the 7th edition of the tumor-node-metastases
(TNM) classification of the American Joint Committee
for Cancer Staging and the Revised International System
for staging lung cancer [14].
The decision to proceed with segmentectomy or lob-
ectomy was based primarily on surgeon preference for
the management of stage I NSCLC; however, preopera-
tive cardiopulmonary reserve, preoperative imaging, and
comorbidities also influenced procedure selection on a
patient-by-patient basis. Operative reports were reviewed
and patients were excluded from analysis if the anatomic
resection was not associated with identification, isolation,
and individual division of the segmental broncho-vascular
structures (i.e. extended wedge resection). The surgical ap-
proach was left to the discretion of the surgeon and in-
cluded various open thoracotomy incisions or VATS
(Table 1). Mediastinal, hilar, and interlobar lymph node
sampling or dissection was routinely performed.
A complete evaluation of pulmonary function was car-
ried out in all included patients preoperatively and at
least 6 months following surgical resection, but no later
than 36 months. The indication for obtaining interval
PFT’s was variable, however the majority were obtained
as part of a routine postoperative protocol for patients
undergoing segmentectomy at our institution. Evaluation
of pulmonary function was performed according to the
standards outlined by the American Thoracic Society [15].
Forced expiratory volume in 1 second (FEV1) and diffu-
sion capacity of carbon monoxide (DLCO) were measured
in all patients pre- and postoperatively and were used for
comparison between the types of surgical resection (1–2
segments vs. 3–5 segments). Given FEV1 and DLCO are
the best-known spirometric predictors of postoperative
morbidity and mortality, other spirometric values were
not included in our analysis [16]. In cases where multiple
measurements were reported for each value (i.e. pre- and
post- bronchodilator treatment), the greatest measure-
ment was used for the analysis. Observed measurements
Table 2 Distribution by segments resected
Type of resection N = 159
3-5 segments 82
Right upper lobe 28
Right lower lobe 12
Right basilar segments 8
Left upper lobe 12
Left lower lobe 13
Left basilar segments 9
1-2 segments 77
Right apical segment 11
Right anterior segment 4
Right posterior segment 9
Right apicoposterior segments 3
Right middle lobe 5
Right medial segment 2
Right lateral segment 2
Right superior segment 9
Left upper division segments 17
Left lingular segments 4
Left anterior segment 1
Left apicoposterior segment 5
Left superior segment 5
Table 3 Preoperative, postoperative, and mean decline
in PFT’s
1-2 Segments 3-5 Segments P value
(n = 77) (n = 82)
Preoperative PFT’s
FEV1 (observed) (L) 1.95 ± 0.7 2.15 ± 0.7 0.085
FEV1 (% predicted) 79% ± 23 85% ± 21 0.038
DLCO (observed) 14.6 ± 5.4 16.6 ± 5.0 0.056
DLCO (% predicted) 63% ± 22 73% ± 19 0.010
Postoperative PFT’S
FEV1 (observed) (L) 1.85 ± 0.7 1.86 ± 0.6 0.726
FEV1 (% predicted) 75% ± 22 77% ± 21 0.631
DLCO (observed) 13.3 ± 5.8 14.2 ± 5.3 0.298
DLCO (% predicted) 60% ± 21 67% ± 22 0.060
Decline in PFT’s
FEV1 (obs) (L) 0.1 ± 0.3 0.3 ± 0.4 0.003
FEV1 (% predicted) 4.3% ± 17.4 8.2% ± 16.7 0.055
DLCO (obs) (mL/min/mmHg) 1.3 ± 3.5 2.4 ± 3.6 0.015
DLCO (% predicted) 3.6% ± 15.8 5.9% ± 20.1 0.280
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height, and weight were included for analysis. The primary
outcome in our study was the absolute and percent
change from the preoperative observed and percent stand-
ard values for FEV1 and DLCO, which will be referred to
as FEV1 (observed), FEV1 (% predicted), DLCO (observed), and
DLCO (% predicted) in the remainder of the text.
Categorical variables (sex, approach, and tumor loca-
tion) are reported as frequency and percentage with the
Fischer’s exact test being used for comparative analysis.
Continuous variables (age, tumor size, time of follow-up,
and PFT results) are reported as mean with standard de-
viation or median with range, as appropriate. Compara-
tive analysis of PFT results, including preoperative and
postoperative values, as well as absolute and percent
change was performed using the Mann–Whitney U test.
Comparative analysis of preoperative and postoperative
PFT results for each cohort was performed using the
paired Student t-test. All comparisons were two-tailed.
A p-value of 0.05 or less was considered statistically sig-
nificant. The statistical package STATA, version 11.2
(College Station, TX) was used for the analyses.
Results
Median follow-up, determined as the time of resection
to the time of postoperative pulmonary function testing,
was approximately 1 year for both groups (1–2 seg-
ments: 11.8 months, range 6.0 to 27.0; 3–5 segments
11.9 months, range 6.0 to 35.3; p = 0.952). Preoperative
demographics, tumor characteristics, and operative de-
tails are shown in Table 1. No significant differences
were noted in age or sex distribution when comparing
the two cohorts. Patients who had 3–5 segments
resected tended to have larger tumors (2.9 ± 1.9 centime-
ters) compared to those who had 1–2 segments resected
(1.9 ± 0.9 centimeters, p = <0.001). Nearly three times as
many segments were resected in those who underwent
resection of 3–5 segments (4.0 ± 0.8 vs. 1.4 ± 0.5, p =
<0.001). Fewer patients were resected via thoracotomy
in the lesser resection cohort, though this difference was
not statistically significant (35.1% vs. 45.1%, p = 0.257).
Left upper lobe tumors were treated more frequently
with resection of 1–2 segments (i.e. upper division seg-
mentectomy or lingulectomy), whereas 3–5 segment re-
sections were more commonly used to treat lower lobe
tumors (Table 1). The distribution of segments and lobes
resected is noted in Table 2.
PFT results for each cohort are detailed in Table 3. Pa-
tients undergoing resection of fewer anatomic segments
had worse overall baseline pulmonary function prior to re-
section in regards to both FEV1 and DLCO. Parenchymal-
sparing resections (1–2 segments) resulted in better pres-
ervation of postoperative pulmonary function compared
to larger resections (3–5 segments) as demonstrated by
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p = 0.003), FEV1 (%predicted) (4.3% vs. 8.2%; p = 0.055), and
DLCO (observed) (1.5 vs. 2.6 mL/min/mmHg; p = 0.015).
However, the decline in DLCO (%predicted) (3.6% vs. 5.9%;
p = 0.280) was not significantly different between resection
groups. The mean percent decline in FEV1 and DLCO for
patients undergoing resection of 1–2 and 3–5 segments is
shown graphically in Figure 1.
The results of the paired analysis comparing preopera-
tive and postoperative values within each resection co-
hort are represented in Figure 2. The decline in DLCO
(%predicted) was not statistically significant following resec-
tion of 1–2 segments, whereas all other spirometric
values analyzed declined significantly in both resection
cohorts.Discussion
Beyond the arguments related to the oncologic adequacy
of sublobar resection for the peripheral stage I lung can-
cer [17-19], a key component of determining the role of
anatomic segmentectomy in the treatment of early-stage
NSCLC involves evaluation of the theoretical advantage
of better preservation of pulmonary function compared
to lobectomy. To date, this question has received much
less attention than the issues of morbidity, mortality,
disease-free survival and overall survival. In addition, the
few efforts focusing on this issue have yielded contradic-
ting and controversial results [8,10-13]. Small patient
populations, as well as variability in baseline pulmonary
function and specific pulmonary function values re-
ported in these studies have made it difficult to defini-
tively validate this theory. To our knowledge, the
current study represents the largest cohort of patients
undergoing segmentectomy with pre- and postoperative
pulmonary function testing available for comparison
with lobectomy.Figure 1 Mean percent decline in PFT’s.In the last two decades, there have been two studies
comparing sublobar to lobar resection that have con-
cluded that lesser resection does not provide an advan-
tage in preservation of pulmonary function. The Lung
Cancer Study Group reported statistically significant
preservation of forced vital capacity (FVC) and FEV1 at
6 months postoperatively in favor of sublobar resection,
however, after 12–18 months the benefit in FVC was no
longer noted [8]. Interestingly, the authors stated that
there was no difference in postoperative function be-
tween sublobar resection and lobectomy despite the per-
cent difference of FEV1 remaining significant at 12–18
months (−5.2% vs. -11.1%; p = 0.041). Takizawa and col-
leagues compared anatomic segmentectomy to lobec-
tomy for the treatment of small, peripheral NSCLC in a
non-randomized, propensity-matched analysis [10]. They
reported no difference in the change of FVC pre- and
postoperatively at one year. However, a small but signifi-
cant preservation in FEV1 following segmentectomy
compared to lobectomy was noted.
In contrast, there have been three comparative studies
that have provided data in support of better preservation
in pulmonary function following segmentectomy.
Harada and colleagues reported a significant benefit in
preservation of FEV1 (p = 0.0007) and FVC (p = 0.0006) at
six months following segmentectomy compared to lobec-
tomy in patients with good baseline pulmonary function
and stage I NSCLC’s less than 2 centimeters [11]. This
study also demonstrated a significant correlation between
number of segments resected and decrease in postopera-
tive FEV1 (p = <0.0001) and FVC (p = <0.0001). Keenan
and coworkers compared segmentectomy and lobectomy
in the treatment of stage I NSCLC and found a significant
decrease in FEV1, DLCO, and FVC at one year following
lobectomy, whereas only DLCO declined significantly after
anatomic segmentectomy [12]. Unlike the study by Harada
et al., baseline FEV1 and DLCO were significantly worse in
the segmentectomy cohort. Lastly, Martin-Ucar and col-
leagues compared changes in pulmonary function in a
matched analysis of high-risk patients (predicted postoper-
ative FEV1 < 40%) with stage I NSCLC treated with seg-
mentectomy or lobectomy [13]. An increase in FEV1 was
actually noted following segmentectomy in this study, in
contrast to a significant decrease following lobectomy
(12% vs. -12%; p = 0.02).
We took a slightly different approach in the present
study. Since the purpose of our study was to determine if
parenchymal sparing resections resulted in better preser-
vation of pulmonary function, we chose to group patients
by number of segments resected rather than simply com-
paring segmentectomies and lobectomies. Basilar seg-
ments are comprised of 4 pulmonary segments with the
volume of lung resected more closely approximating that
of a lobectomy, with the exception of 2 segment middle
Figure 2 Changes in pulmonary function based on paired analysis within each resection cohort.
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of segmentectomies in this series (17/89). In a separate
analysis not included here, we found that when we
compared all segmentectomies to lobectomies there
was a trend toward preserved pulmonary function in
the segmentectomy cohort, although none of these dif-
ferences reached statistical significance. We suspect
that the large proportion of basilar segmentectomies
skewed these results given the greater volume of lung
parenchyma resected relative to other segmentec-
tomies. By grouping patients into 1–2 segment and 3–
5 segment resections, more homogeneous cohorts
were created based on volume of parenchyma resected.
Similar to the previously mentioned studies [11-13],
we found that lesser resection resulted in better preser-
vation of postoperative FEV1 at a median follow up
time of 1 year. The question then becomes, is this dif-
ference clinically significant? Several Japanese authors
have stated that a loss 200 mL or greater in FEV1 may
be important when considering sublobar resection or
lobectomy for patients with marginal pulmonary re-
serve [20,21]. Therefore, the mean decline in FEV1(ob-
served) of 107 mL seen following segmental resection of
1–2 segments is less likely to be clinically significant
for most patients, whereas the decline of 286 mL
following resection of 3–5 segments seems more likely
to have a detrimental clinical impact on overallfunctionality and quality of life. Although this differ-
ence appears to be small, the preservation in pulmon-
ary function associated with lesser resection may prove
to be more significant for those patients with marginal
pulmonary function and for those who will require
additional pulmonary resections in the future for treat-
ment of metachronous lung cancers. Similar to the
findings of Keenan and colleagues [12], better preser-
vation of DLCO was also noted in the lesser resection
group. Unlike FEV1, it is less clear what degree of
change in DLCO represents a clinically significant
decline.
Although the decline in both FEV1 and DLCO fol-
lowing resection was less in the 1–2 segment cohort,
only absolute (or observed) decline in FEV1 and DLCO
reached statistical significance when comparing the
two groups. Percent predicted values are derived using
reference values obtained from normal or healthy pa-
tient with similar anthropometric characteristics in-
cluding age, height, gender, and ethnicity. Differences
in predicted values may occur when using different ref-
erence sources [22]. Many patients in our study had ei-
ther preoperative or postoperative testing performed at
outside institutions, where the reference sources used
may have varied. The PFT’s were also performed at two
different points in time, possibly affecting the reference
range used based on patient age. These factors may
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cent predicted difference seen in our study. The abso-
lute change in spirometric values is likely a better
representation of loss in pulmonary function following
resection, as the postoperative results can be com-
pared to each individual patient’s baseline function.
Our study does have a number of limitations, includ-
ing its retrospective nature and the inherent associ-
ated selection bias. A greater proportion of patients
underwent thoracotomy in the 3–5 segment cohort,
which may have had a negative impact on follow-up
pulmonary function. However, this effect should have
been minimized at a median follow-up of 1 year. The
indication for obtaining postoperative PFT’s in the
current series was variable. Although most PFT’s were
obtained as part of our routine postoperative screen-
ing, other indications did not preclude inclusion into
the study. Patient effort is an uncontrollable variable
that also likely accounted for some variation in PFT
results, a problem that is inherent to effort-based test-
ing such as PFT. Finally, quality of life measures, such
as exercise testing or need for postoperative oxygen
supplementation, were not included in the current
study.
Conclusion
In conclusion, parenchymal-sparing resections resulted
in better preservation of postoperative pulmonary
function in the present series. Functional preservation
at a median of one year following resection of 1–2 ana-
tomic segments was significantly better compared to
resection of 3–5 segments for FEV1 and DLCO, sug-
gesting a long-term functional benefit to parenchymal-
sparing anatomic resections. The results from prospect-
ive randomized studies currently underway in Japan
(JCOG0802/WJOG4607L) and North America (CALGB
140503) assessing the oncologic utility, pulmonary func-
tional changes, and quality of life following sublobar re-
section versus lobectomy for stage I NSCLC will
provide further insight into the most favorable approach
to early stage NSCLC.
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